Axsome's AXS-05 shows strong efficacy in treating Alzheimer's Disease Agitation, with significant CMAI score reductions.
Clinical Trials Arena on MSN13d
IGC adds new clinical site in Canada for Alzheimer’s agitation therapy trialIGC Pharma has added HHS in Canada as a new clinical site for its Phase II CALMA trial of IGC-AD1 to treat agitation in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback